Bavarian Nordic Receives USD 120 Million Contract for Smallpox and Mpox Manufacturing
BARDA Awards Major Contract to Bavarian Nordic
Key Points:
- Bavarian Nordic has been awarded a USD 120 million contract by the Biomedical Advanced Research and Development Authority (BARDA).
- The contract is for the manufacturing of smallpox and mpox vaccines.
- BARDA has also supported the development of a freeze-dried version of the vaccine with a longer shelf-life.
- Bavarian Nordic has received an additional order for its JYNNEOS smallpox and monkeypox vaccine.
- This latest contract further supports Bavarian Nordic's efforts in combating these diseases.
Additional Information:
The Danish biotechnology company has been awarded a sole-source BARDA contract valued at more than USD 120 million. The Department of Health and Human Services (HHS) will provide approximately 11 million doses of the vaccine to the Strategic National Stockpile.
Bavarian Nordic raised its financial guidance for 2022 for the third time in a month on Friday after receiving the latest contract.
Comments